What are the significant differences in time points and types of vascular benefits seen in LEADER using a GLP-1 RA vs the EMPA-REG trial which evaluated an SGLT2 inhibitor?

What are the significant differences in time points and types of vascular benefits seen in LEADER using a GLP-1 RA vs the EMPA-REG trial which evaluated an SGLT2 inhibitor?

What are the significant differences in time points and types of vascular benefits seen in LEADER using a GLP-1 RA vs the EMPA-REG trial which evaluated an SGLT2 inhibitor?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Lawrence Leiter, MD, FRCP(C), FACP

Lawrence Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism Director, Lipid Clinic Associate Director, Clinical Nutrition and Risk Factor Modification Centre St. Michael’s Hospital Professor of Medicine and Nutritional Sciences University of Toronto Toronto, Ontario